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SUMMARY
Objectives: To reduce the increase of oxidative stress and the upregulation of
CD40L during stenting procedure using ascorbic acid infusion. Background:
CD40L upregulation occurring after coronary Percutaneous Coronary In-
tervention predicts vascular events but the underlying mechanism is still
unclear. Methods: Fifty-six patients undergoing elective coronary stenting
were randomly allocated to intravenous infusion of the antioxidant ascorbic
acid or placebo. Platelet CD40L and plasma levels of soluble CD40L and of
8-hydroxy-2′-deoxyguanosine, a marker of oxidative stress, were measured
before and after coronary stenting. In vitro study was also done to measure
reactive oxidant species and CD40L expression in platelets exposed to anoxia-
reoxygenation.Results: Placebo-treated patients showed a significant increase
of platelet CD40L, soluble CD40L and 8-hydroxy-2′-deoxyguanosine com-
pared to baseline values. Patients given ascorbic acid showed no change of
soluble CD40L and platelet CD40L but a significant decrease of 8-hydroxy-
2′-deoxyguanosine. After 60 and 120 min, soluble CD40L, platelet CD40L
and 8-hydroxy-2′-deoxyguanosine were significantly lower in the ascorbic
acid-treated group compared to the placebo-treated one. A significant correla-
tion between platelet CD40L and soluble CD40L and between soluble CD40L
and 8-hydroxy-2′-deoxyguanosine was observed. Platelets, in vitro exposed to
anoxia-reoxygenation, had a burst of ROS and an upregulation of CD40L that
were inhibited by ascorbic acid or apocynin, an inhibitor of NADPH oxidase.
Conclusions: This study shows that in patients undergoing coronary stenting
CD40L is upregulated with a mechanism which is likely mediated by oxidative
stress.
Introduction
Despite intracoronary stents improved survival in pa-
tients with coronary heart disease who underwent per-
cutaneous coronary intervention (PCI), stent thrombosis
(2.03%), and vascular events such as myocardial infarc-
tion, stroke, and vascular death (11.9%) are still observed
in a high percentage of patients undergoing PCI [1–3].
Platelets have a key role in such poor outcomes as shown
by the fact that reduction of vascular outcomes is related
to the rate of platelet inhibition [3–5]. Knowledge of the
mechanisms of coronary stent-related platelet activation
is still unclear.
CD40L is a cytokine of the tumor necrosis factor alpha
(TNF)α super-family primarily identified in the immuno-
system cells [6]. CD40L is expressed on platelet surface
upon agonist stimulation and is released in the circu-
lation as soluble form (sCD40L) [7]; more than 95%
of the circulating CD40L stems from platelet activation
[8]. CD40L is a potent inflammatory and procoagulant
molecule that is over-expressed in a series of clinical set-
tings characterized by accelerated atherosclerosis, such as
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hypercholesterolemia [9], diabetes [10], and smoking
[11]. Prospective studies have shown that CD40L is pre-
dictive of poor vascular outcome in patients with acute
vascular events or at risk of both thromboembolic and
atherothrombotic diseases [12–14]. Furthermore, in pa-
tients undergoing PCI the increase of CD40L immedi-
ately after stenting procedure seems to be associated with
restenosis [5,15]. Thus comprehension of the mechanism
leading to the increase of CD40L could be relevant not
only to provide a mechanistic insight but also to eventu-
ally develop novel therapeutic strategies. We, as well as
others, have reported that oxidative stress plays a major
role in the upregulation of CD40L [16–18]. Interestingly,
in patients undergoing PCI, a significant increase of ox-
idative stress has been reported as a likely consequence
of the ischemia-reperfusion process occurring in this set-
ting [19–22]. We, therefore, speculated that the increase
of oxidative stress may be pertinent in the upregulation
of CD40L and that the use of an antioxidant during stent-
ing procedure could minimize this phenomenon. To ex-
plore the validity of such hypothesis we planned a pi-
lot study consisting in measuring CD40L before and after
coronary stenting in patients treated or not with ascor-
bic acid, a known antioxidant that scavenges superoxide
radicals [23]. This approach was based on the results of a
previous study demonstrating that intravenous infusion
of 1 g ascorbic acid is associated with a significant decrease
of circulating sCD40L [24]. As ischemia-reperfusion phe-
nomenon could be a part of the injury linked to PCI, we
performed in vitro study to see if anoxia-reoxygenation
of platelets was associated with oxidative-stress mediated
CD40L upregulation.
Materials and Methods
Interventional Study
Study Population and Study Design
This prospective randomized pilot study included patients
≥18 years of age with clinically stable class I or II ef-
fort angina, a positive functional study for myocardial
ischemia and a single de novo lesion in a native coro-
nary artery referred to Department of the Heart and Great
Vessels “Attilio Reale,” University of Rome “La Sapienza,”
Italy between June 2008 and January 2009.
Angiographic inclusion criteria were all type A or
type B coronary lesions, as described by the American
College Cardiology (ACC)/American Heart Association
(AHA) Task Force [25], a target vessel reference diameter
of 2.5–3.5 mm, a lesion length ≤33 mm, which would be
covered with a single medicated stent, diameter stenoses
≥70% and <100%, and a Thrombolysis In Myocardial
Infarction grade >1 flow.
Procedural exclusion criteria were a target vessel diam-
eter <2.5 mm or >4.0 mm (14 patients), type C lesions
(four patients) and bifurcation lesions (four patients).
Clinical exclusion criteria were: contraindication to as-
pirin or clopidrogel (two patients), previous myocardial
infarction (three patients), graft vessel disease (four pa-
tients), platelet count <100,000/mm3 (two patients), his-
tory of bleeding diathesis (two patients), renal dysfunc-
tion (creatinine levels >1.5mg/dL) (one patient).
The study was approved by the University of Rome “La
Sapienza” Ethical Committee, and written informed con-
sent was obtained from all patients.
Fifty-six consecutive patients [47 male and 9 female,
mean ages 67 (50–84) years] who met inclusion and ex-
clusion criteria entered the study.
The PCI was carried out according to international
guidelines, using a standard technique, through the
femoral route [25]. Systematic stent implantation was
achieved in all patients. The sheath was removed imme-
diately at the end of the procedure in all cases. Routine
care before and after the procedure was undertaken for
all patients, including pretreatment clopidogrel (600-mg
initial bolus) 12 h before the procedure followed by 75mg
daily for at least 1 year. In addition, all patients received
aspirin, 100mg daily, for at least 1 week before, with a
dose administered 12 h before stenting.
Serum cardiac-Troponin I (cTpI) was measured at base-
line before the procedure, every 6 h over the next 2 days
and thereafter if abnormal values were present. Left ven-
tricular ejection fraction (LVEF) was calculated by the bi-
plane Simpson’s rule, as recommended by the American
Society of Echocardiography at baseline and at 72h after
PCI by operators unaware of the treatment allocation.
Angioplasty Procedure
Preparation and percutaneous access were performed ac-
cording to standard hospital procedures. After percu-
taneous access was obtained, an intravenous bolus of
5000U of unfractionated heparin was administered, with
sufficient supplements (if necessary) to maintain an ac-
tivated clotting time (ACT) ≥250 seconds during inter-
ventions. A baseline angiography of the involved vessel
was performed in at least two near orthogonal views that
showed the target lesion free of foreshortening or vessel
overlap, using a 6 F diagnostic catheter. The angiograms
included at least 2 cm of catheter to allow for accurate
quantitative coronary angiographic measurements.
Selective angiography was performed with an auto-
matic injector (ACIST HD101, Eden Prairie, Minnesota),
by using a total volume of 10 mL iopromide (Ultravist
370, Schering AG, Berlin, Germany), at a rate of 2.0mL/s
for left coronary arteries, and a total volume of 8mL
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iopromide at a rate of 1.0mL/s for right coronary ar-
teries, at 450 PSI. Following identification of the tar-
get lesion that meets all eligibility criteria, those patients
who continue to meet eligibility criteria were randomized
to placebo or ascorbic acid administration and received
a unique study identification code. Thus, after baseline
collection of blood samples a sealed, opaque envelopes
containing a computer-generated random sequence were
used for randomization to an intravenous infusion of
ascorbic acid (1 g/L at 24mg/min) or placebo (saline
solution).
The target lesion was crossed with a 0.014 exchange-
length guide wire and a single predilatation with an ap-
propriately sized balloon was performed by inflating the
balloon to the nominal pressure over a 15 sec period.
Within 1 min from balloon dilatation a sirolimus-eluting
stent (SES; CypherTM, Cordis, Johnson & Johnson) was
implanted. Stent deployment was achieved with high
pressure balloon inflation (more than 15 atm) lasting
10 sec without any post-dilatation. No direct stenting was
performed.
Laboratory Analysis
To ensure blind analysis, cardiologists sent tube identified
by numerical code to the laboratory where biologists per-
form analytical tests. The randomization list was unveiled
after that the analytical phase was terminated.
Blood Sampling Protocol for Platelet Isolation
Blood samples were drawn from an antecubital vein
with a 21-gauge needle and then mixed in a tube with
0.13mM/l sodium citrate (ratio 9:1) for plasma prepara-
tion. Samples were collected before and 60, 120 min af-
ter the procedure. To obtain platelet rich plasma (PRP)
sample was centrifuged (15 min at 180 g) as previously
reported [26].
sCD40L, 8-hydroxy-2′-deoxyguanosine (8OH-dG),
high sensitivity C-reactive protein (hs-CRP), TNFα, and
Troponin.
Blood samples were immediately centrifuged at 300 g
for 20 min at 4◦C, and the supernatant was collected
and stored at −80◦C until measurement. Plasma levels of
sCD40L, 8OH-dG and serum levels of hs-CRP were mea-
sured with a commercial immunoassay (Tema Ricerche
s.r.l., Bologna, Italy). Intra-assay and interassay coeffi-
cients of variation were 5 and 7% for sCD40L, 2.1 and
4.5% for 8OH-dG, 8.3 and 7.8% for hsPCR, respectively.
TNFα (Quantikine R&D Systems, Minneapolis, MN, USA)
were measured with a commercial immunoassay (Intra-
assay and interassay coefficients of variation were 5.3 and
6.8%). cTp I levels were measured using an automated
enzyme immuno-assay system (Dimension RXL MAX,
Siemens Healthcare diagnostic, Germany) with upper
limit of normal being 0.05 ng/mL in our laboratory.
Flow Cytometric Analysis of Platelet CD40L
Expression
CD40L expression on platelet membranes was ana-
lyzed with specific fluorescein isothiocyanate-labeled
monoclonal antibodies (mAbs; anti-CD40L antibody by
Beckman Coulter). The binding of the primary antibody
was detected with a secondary antibody (anti-mouse
IgG-FITC by Beckman Coulter). In all assays, an irrel-
evant isotype-matched antibody was used as a negative
control.
Blood samples were centrifuged to obtain PRP and im-
mediately fixed with tromboFix platelet stabilizer (Beck-
man Coulter) (30 min at room temperature before any
other treatment). After fixing procedure, twenty micro-
liters of mAb were added to 200μL of platelet suspension
(2 × 108/mL). The unbound mAb was removed by addi-
tion of 0.1% bovine serum albumin–phosphate buffered
saline (PBS) and centrifugation at 300 g for 3 min (twice).
Fluorescence intensity was analyzed by an Epics XL-MCL
cytometer (Coulter Electronics) equipped with an argon
laser at 488 nm. For every histogram, 50,000 platelets
were counted to determine the proportion of positive
platelets. Antibody reactivity is reported as mean fluo-
rescence. Intra-assay coefficient of variation was 5%. To
test the effect of fixing procedure on the functional in-
tegrity of platelet unfixed and fixed samples were in-
cubated after centrifugation with mAB anti-PAC1-FITC
(Beckman Coulter) (an antibody that recognizes an epi-
tope on the glycoprotein IIb/IIIa of activated platelets)
showing that PAC1 binding did not change before and
after centrifugation.
In Vitro Study
Blood Sampling Protocol and Platelet Preparation
Five non-smoking healthy volunteers (three males and
two females, mean age 60 ± 3 years) who had not in-
gested any drug known to interfere with platelet func-
tion for at least 15 days, after having given informed con-
sent, were enrolled for the study. All subjects had fasted
for 12 h before venipuncture and blood samples were
drawn between 8:00 and 9:00 am. Platelet suspension
was obtained as described earlier with a final platelet con-
centration of 2 × 108/mL. Platelets were incubated with
apocynin (25, 50, and 100μM), an inhibitor of NADPH
oxidase, Vitamin C (25, 50, and 100μM) and apoc-
ynin (25, 50, and 100μM) plus Vitamin C (25, 50, and
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100μM). To keep platelets in anaerobic conditions, sam-
ples were purged with a gentle stream of pure nitrogen
gas up to 20 min. Platelets were reoxygenated by re-
exposure to atmospheric conditions. Platelets exposed to
a gentle stream of room air were used as control.
Flow Cytometric Analysis of Platelet Reactive
Oxidant Species (ROS) Formation and CD40L
To detect the platelet formation of ROS, the property
of DCF-DA was used. This molecule rapidly diffuses
across cell membranes and is then trapped within the
cell via a deacetylation reaction. In the presence of
hydrogen peroxide, this compound is oxidized to the
highly fluorescent dichlorofluorescein (DCF). DCFH-DA
was added to platelet suspension (final concentration:
40μmol/L) immediately after the anoxia phase; fluores-
cence intensity was analyzed on an Epics XL-MCL cy-
tometer (Coulter Electronics) equipped with an argon
laser at 510–550nm (green). For every histogram, 50,000
platelets were counted to determine the proportion of
positive platelets. The fluorescent signal generated by the
probe was expressed as mean fluorescence. CD40L ex-
pression on platelet membrane was analyzed as earlier
described.
Intra-assay coefficient of variation was 5%.
Statistical Analysis
Two-sided t-test was used to compare means. Re-
sults were confirmed by nonparametric tests as Mann-
Whitney U-test. Pearson chi-square test was used to com-
pare proportions. Friedman testing was performed for
evaluating differences over time within the group. Dif-
ferences between paired data were tested by Wilcoxon
rank testing. The Spearman correlation coefficient was
calculated to assess the correlation of absolute change
from the baseline of sCD40L plasma levels (sCD40L),
8-OHdG plasma levels (8-OHdG), platelet CD40L
expression (platelet CD40L expression), and LVEF
(LVEF). Data are presented as mean (1 SD) or as median
and interquartile range (IQR) (25th, 75th percentile).
Statistical significance was defined at P < 0.05. Statisti-
cal analysis was performed with SPSS 13.0 software for
Windows.
Sample size determination: we computed the mini-
mum sample size with respect to a two-tailed one-sample
Student t-test with Welch correction, considering a (1)
difference for CD40L variation to be detected between the
patients treated or not with Vitamin C |δ| ≥ 1.5, (2) stan-
dard deviations SD = 1 for the control group and 1.2 for
the Vitamin C group, (3) type I error probability α = 0.05
and power 1-β = 0.90. This resulted in a minimum sam-
ple size of n = 10 for control and n = 12 for Vitamin C
group, which are increased to n > 20.
Results
Characteristics of the Study Population
Table 1 shows baseline demographic and clinical charac-
teristics of included patients. Angiographic and procedu-
ral data are shown in Table 2. The two groups assigned
to ascorbic acid or placebo did not differ in terms of car-
diovascular risk factors and pharmacological therapy. The
implantation of single stent was successful in all patients
with complete covering of the vessel lesion length and
without visual residual stenosis within the stent. Fur-
thermore, angiographic images obtained following stent
deployment did not show signs of endothelial dissection
in the areas proximal or distal to the stent struts. No
side effects were observed during or after ascorbic acid
or placebo infusion.
Baseline mean values of LVEF were similar in both
Vitamin C and control groups (52.3 ± 4.3% vs. 53.7% ±
3.9%, P = ns).
Ascorbic acid assigned group showed, at the baseline,
similar values of sCD40L (2.3 ± 1.4 vs. 2.3 ± 1.2 ng/mL,
P = 0.959), 8-OHdG (3.7 ± 1.3 vs. 3.7 ± 1.1 ng/mL,
P = 0.373), hs-CRP [Median (IQR):1.0 (0.71–1.90) vs.
1.25 (0.80–2.00)mg/L, P = 0.451) and TNF-α [42.5
(35.0–50.0) vs. 40.0 (40.0–50.0) pg/mL, P = 0.735) com-
pared to placebo group. The platelet CD40L expression
was similar the in two groups (4.2 ± 0.88 MF in ascorbic
acid assigned group and 4.3 ± 0.78 MF in placebo group,
P = 0.0724), the apparent trend in differences between
Table 1 Baseline clinical characteristics
Placebo P-value Vitamin C
(n = 28) (n = 28)
Age (years) 68 ± 9 >0.05 66 ± 8
Male, n (%) 23 (82) >0.05 24 (86)
Familiarity, n (%) 17 (61) >0.05 14 (50)
Hypertension, n (%) 20 (71) >0.05 20 (71)
Dyslipidemia, n (%) 20 (71) >0.05 19 (68)
Current smoker, n (%) 13 (46) >0.05 11 (39)
Diabetes mellitus, n (%) 15 (54) >0.05 18 (64)
Pharmacological therapy
Oral hypoglycaemic, n (%) 12 (43) >0.05 11 (39)
Insulin treatment, n (%) 2 (7) >0.05 3 (10)
Statins, n (%) 19 (68) >0.05 16 (57)
Nitrates, n (%) 13 (46) >0.05 16 (57)
ACE-inhibitors, n (%) 15 (54) >0.05 12 (43)
β-blockers, n (%) 9 (32) >0.05 10 (36)
Ca-antagonists, n (%) 7 (25) >0.05 6 (21)
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Table 2 Angiographic characteristics and quantitative angiographic measurements of included subjects
Placebo (n = 28) P-value Vitamin C (n = 28)
Target vessel Left anterior descending artery, n (%) 18(64) >0.05 15 (54)
Left circumflex artery, n (%) 3 (11) >0.05 6 (21)
Right coronary artery, n (%) 7 (25) >0.05 7 (25)
Procedural data Diameter stenosis (%) 80.1 ± 9.7 >0.05 83.5 ± 11.5
Stent diameter (mm) 3.0 ± 0.39 >0.05 3.1 ± 0.37
Stent length (mm) 19.8 ± 7.1 >0.05 20.8 ± 7.5
Balloon pressure (atm) 16.5 ± 1.4 >0.05 16.9 ± 1.1
the two groups is well under the coefficient of variation
of the method.
There were no adverse events during hospitalization in
both Vitamin C and placebo group.
Interventional Study
Serum cardiac-Troponin I and Left Ventricular
Ejection Fraction
The median absolute increase after PCI in serum cTpI
level was similar between controls and ascorbic acid
group [Median (IQR): 0.027 (0.05–0.032) vs. 0.008
(0.02–0.013) ng/mL, respectively, P = 0.0832].
After the intervention, LVEF improved in both groups
with a higher increase in Vitamin C treated patients
(58.3 ± 2.9%) compared to the placebo one (54.1 ±
4.7%) (P < 0.03). Vitamin C-treated patients showed a
greater improvement of LVEF after procedure compared
to that observed in the control group (P < 0.01).
sCD40L Plasma Levels
Compared to baseline, no statistically significant changes
of sCD40L was found after 60 (2.2 ± 1.1 ng/mL, P =
0.269) and 120 min (2.4 ± 1.0 ng/mL, P = 0.738) of
Vitamin C infusion; conversely, a significant increase of
sCD40L was observed after 60 (3.2 ± 1.5 ng/mL, P =
0.0007) and 120 min (3.4 ± 1.7 ng/mL, P = 0.0003) of
placebo infusion (Figure 1, Panel A). Comparing sCD40L
values at 60 and 120 min after balloon inflation, the
ascorbic acid-treated group showed a significant lower
value of sCD40L in respect to placebo group (P = 0.0057
and P = 0.016, respectively) (Figure 1, Panel A). Similar
results were obtained in the subgroup of diabetic patients
(n = 33; 60 min: P = 0.01; 120 min: P = 0.06).
Platelet CD40L Expression
Compared to baseline, platelet expression of CD40L did
not significantly differ at 60 (3.8 ± 1.3 MF, P = 0.077)
and 120 min (3.8 ± 1.1 MF, P = 0.307) after bal-
loon inflation in Vitamin C treated group (Figure 1,
Panel B) (Figure 2, Panel A). On the other hand, in the
placebo group, at 60 (5.1 ± 1.3 MF, P = 0.005) and
120 min (5.4 ± 1.2 MF, P = 0.0002) after balloon infla-
tion, platelet CD40L expression was higher than baseline
(Figure 1, Panel B) (Figure 2, Panel B). A significant
difference between groups was observed at 60 (P =
0.0008) and 120 (P < 0.0001) min after balloon inflation
(Figure 1, Panel B). Similar results were obtained in the
subgroup of diabetic patients (n = 33; 60 min: P = 0.036;
120 min: P = 0.001).
8-hydroxy-2′-deoxyguanosine, hs-CRP, and TNF-α
Compared to baseline, 8-OHdG plasma levels significantly
decreased at 60 (2.6 ± 1.1, ng/mL, P < 0.0001) and
120 min (2.7 ± 0.87 ng/mL, P = 0.0003) after balloon
inflation in Vitamin C treated group (Figure 1, Panel C).
In contrast, the placebo group at 60 (4.2 ± 1.1 ng/mL, P =
0.045) and 120 min (4.6 ± 1.0 ng/mL, P = 0.003) after
balloon inflation, showed 8-OHdG plasma levels higher
than baseline (Figure 1, Panel C). A significant difference
between groups was observed at 60 (P < 0.0001) and
120 min (P < 0.0001) after balloon inflation (Figure 1,
Panel C).
Hs-CRP [Vitamin C: 1.0 (0.67–1.60) and 1.37
(1.0–2.0)mg/L, P > 0.05; Placebo: 1.30 (0.75–2.0) and
1.25 (0.95–2.10)mg/L, P > 0.05] and TNF-α [Vitamin C:
45.0 (40.0–60.0) and 43.5 (36.5–58.5) pg/mL, P > 0.05;
Placebo: 40.0 (40.0–50.0) and 46.5 (40.0–58.0) pg/mL,
P > 0.05] did not show any significant changes in both
groups of treatment at 60 and 120 min after PCI.
Bivariate Analysis
Simple linear regression analysis showed an overall corre-
lation between sCD40L plasma levels and platelet CD40L
expression, sCD40L and 8-OHdG, and between 8-OHdG
and CD40L platelet expression (Figure 1, Panels D–F).
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Figure 1 Plasma levels of sCD40L (PanelA), expression of platelet CD40L (Panel B), plasma levels of 8OHdG (Panel C) in patients treated with (black box)
or without (white box) Vitamin C infusion. Simple linear correlation between platelet and soluble CD40L (Panel D), 8OHdG and both soluble and platelet
CD40L (Panels E and F) before and after 10, 60, and 120 min after coronary stenting ∗P < 0.05; data are expressed as mean ± SE.
These correlations have been observed at each study time
(data not shown). Hs-CRP and TNF-α did not show any
statistically significant correlations with sCD40L plasma lev-
els, platelet CD40L expression and 8-OHdG serum levels
at each study time (data not shown).
We further analyzed the correlation between abso-
lute change from the baseline in plasma concentrations
of sCD40L, 8-OhdG, and platelet CD40L expression. Af-
ter 60 min of Vitamin C or Placebo infusion, absolute
change from the baseline of plasma concentrations of
sCD40L correlated positively with both 8-OHdG plasma
levels (Spearman R = 0.44, P = 0.0006) and platelet
CD40L expression (Spearman R = 0.33, P = 0.014); thus,
8-OHdG plasma levels correlated positively with
platelet CD40L expression (Spearman R = 0.36, P =
0.006). Similar data was observed after 120 min of
Vitamin C or Placebo administration. 8-OHdG plasma
levels directly correlated with sCD40L plasma lev-
els (Spearman R = 0.40, P = 0.002) and platelet
CD40L expression (Spearman R = 0.48, P = 0.0002).
sCD40L plasma levels did not significantly correlate
with platelet CD40L expression (Spearman R = 0.22,
P = 0.102) after 120 min of experimental drugs.
sCD40L plasma levels, measured after 120 min of Vi-
tamin C or Placebo administration, showed a statistically
significant inverse correlation with LVEF evaluated 72h
after coronary stenting (Spearman R = −0.35, P <
0.02).
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Figure 2 ArepresentativeflowcytometricanalysisofCD40L fromplacebo
group (panel A) or Vitamin C treated patients (panel B).
In Vitro Study
Flow Cytometric Analysis of Platelet ROS Formation
and CD40L Expression
Platelets that underwent anoxia-re-oxygenation showed
higher values of ROS compared to control platelets
(time 0). The burst of platelet ROS depended on the
time of anoxia exposure (5, 10, 20 min). Incubation
with scalar doses, singularly added or together, of ascor-
bic acid (25, 50, and 100μM) and apocynin (25, 50,
and 100μM) dose dependent and sinergically blunted
anoxia-re-oxygenation induced platelet ROS formation
(Figure 3).
Similarly to ROS formation, platelet expression of
CD40L significantly increase in anoxic condition com-
pared to control platelets (time 0). The CD40L platelet ex-
pression depended on the time of anoxia exposure (5, 10,
20 min). Treatment with scalar doses, singularly added or
together, of ascorbic acid (25, 50, and 100μM) and apoc-
ynin (25, 50, and 100μM) dose dependent and siner-
gically inhibited anoxia-re-oxygenation induced platelet
CD40L expression (Figure 4).
Discussion
The study provides evidence that oxidative stress is impli-
cated in upregulating CD40L expression in patients un-
dergoing coronary stenting.
Previous studies have shown that sCD40L increased
after angioplasty [27] and suggested that this reflects
platelet activation occurring after interventional proce-
dure [5]. This change was usually observed 24 h after
coronary angioplasty; therefore, it was unclear if sCD40L
increase was an early or a late phenomenon.
Figure 3 ROS production in platelets that underwent anoxia-re-
oxygenation (0, 5, 10, and 20 min) pretreated or not with apocynin (25,
50, 100μM), Vitamin C (25, 50, 100μM) or a combination of the two.
∗∗P < 0.001 versus platelets kept at room air; ∗P < 0.001 versus un-
treated platelets exposed to a same anoxic time. Data are expressed as
mean ± SE.
Our study shows that as early as 60 min after coronary
stenting, sCD40L and platelet CD40L had a significant in-
crease. Platelet CD40L and sCD40L were significantly cor-
related 60 min but not 120 min after coronary stenting;
this might suggest that the late increase of sCD40L may
not only be platelet-related but also involve other cellular
sources of CD40L, even if to a minor extent.
The increase of sCD40L after coronary angioplasty has
been consistently associated with deleterious outcomes
[5,15]. This association has been interpreted as a conse-
quence of the inflammatory and endothelial cell prolifer-
ation effect of CD40L [5]. Thus, knowledge of the mech-
anisms eliciting PCI-induced CD40L upregulation may be
useful to eventually counteract its deleterious effects.
We, along with others, have previously shown that
oxidative stress is implicated in CD40L upregulation
with a mechanism involving the activation of NADPH
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Figure 4 CD40L expression in platelets that underwent anoxia-re-
oxygenation (0, 5, 10, and 20 min) pretreated or not with apocynin (25,
50, 100μM), Vitamin C (25, 50, 100μM) or a combination of the two.
∗∗P < 0.001 versus platelets kept at room air; ∗P < 0.001 versus un-
treated platelets exposed to a same anoxic time. Data are expressed as
mean ± SE.
oxidase [28,29]. Therefore, in patients lacking this en-
zyme, platelet CD40L was down-regulated and normal
platelets, incubated in vitro with apocynin, an inhibitor
of NADPH oxidase, showed lower expression of CD40L
[28]. Also, intravenous infusion of 1 g ascorbic acid re-
sulted in a significant reduction of both platelet CD40L
and sCD40L [24].
Using different markers of oxidative stress, previous
studies showed that oxidative stress increased after PCI
as a likely consequence of the burst of ROS occurring af-
ter ischemia-reperfusion [19–22]. Based on these data we
planned a pilot study to see if ascorbic acid infusion was
able to counteract the increase of CD40L occurring after
PCI. We observed that such treatment was able to pre-
vent both sCD40L and platelet CD40L expression occur-
ring after coronary stenting with a mechanism that was
likely dependent upon its antioxidant effect. Thus intra-
venous infusion of ascorbic acid was associated with a
significant reduction of 8-OHdG plasma levels. Even if it
has been underscored that ascorbic acid may exert an-
tioxidant effect in vivo only at millimolar concentration
[30], it is noteworthy that such concentration can be
achieved in vivo when ascorbic acid is intravenously given
[31]. So, it is plausible that the decrease of serum 8-OHdG
might be attributable to its antioxidant effect.
Together, these data lead to hypothesize that the burst
of ROS occurring after coronary stenting may trigger
platelets CD40L upregulation. This hypothesis is con-
sistent with the fact that sCD40L and platelet CD40L
showed a significant correlation with 8-OHdG levels.
To further corroborate the role of ROS in upregulating
platelet CD40L, the ischemia-reperfusion phenomenon
occurring after coronary stenting was mimicked in vitro
by exposing platelets to anoxia-re-oxygenation. This phe-
nomenon has been proved to be associated with NADPH
oxidase-dependent ROS formation [32,33]. Through this
experiment we demonstrated that platelets CD40L up-
regulation occurs after platelet exposure to anoxia-re-
oxygenation and that such effect was likely mediated
by NADPH oxidase-generated platelet ROS. Thus, an
inhibitor of NADPH oxidase as well as ascorbic acid,
prevented both platelet ROS and CD40L upregulation
elicited by anoxia-re-oxygenation in a dose dependent
and sinergical manner. As NADPH oxidase is the most
important cellular producer of superoxide anion [34] and
ascorbic acid is an antioxidant able to scavenge it [24], it is
conceivable that anoxia-re-oxygenation-induced platelet
CD40L upregulation is mediated by a burst of superoxide
anion.
The study has limitations and implications. Even if we
postulate that NADPH oxidase- generating platelet ROS
is responsible for enhanced oxidative stress and in turn
platelet CD40L upregulation, our study did not provide
evidence that this enzymatic pathway is actually activated
after coronary stenting. Despite the fact that experimen-
tal study seems to support such hypothesis [35], further
investigation in humans is necessary to explore the role
of NADPH oxidase in the ROS formation occurring after
coronary stenting.
The lack of correlation between hs-CRP and CD40L ob-
served in the present study could be explained by a dif-
ferent pattern of platelet activation and inflammation in
the early phase after coronary stenting. In fact CRP serum
levels reach peak values at mean interval of 49 h after
coronary stenting [36] while oxidative stress and CD40L
have a much earlier increase.
We observed that LVEF, a good predictor of stent
thrombosis [37], significantly and inversely correlated
with plasma sCD40L after PCI and was moderately im-
proved in Vitamin C treated group. Nevertheless, a longer
follow-up and a larger study need to be planned to
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confirm the clinical validity of ascorbic acid infusion in
this setting.
As we used a standardized treatment including dual an-
tiplatelet treatment with clopidogrel and aspirin, the en-
hanced level of sCD40L after stenting procedure suggests
that such therapeutic approach is insufficient to counter-
act PCI-induced platelet CD40L release and that. ascorbic
acid may represent a simple and cheap approach to coun-
teract it.
In conclusion, we provide evidence that platelet CD40L
upregulation occurring after coronary stenting could be
oxidative stress-mediated and could be dependent upon
NADPH oxidase activation. Interventional trials with
ascorbic acid will be needed to evaluate if intravenous in-
fusion of ascorbic acid could reduce vascular outcomes in
patients undergoing coronary stenting.
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